Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Using In Vitro Pull-Down and In-Cell Overexpression Assays to Study Protein Interactions with Arrestin.

Perry NA, Zhan X, Gurevich EV, Iverson TM, Gurevich VV.

Methods Mol Biol. 2019;1957:107-120. doi: 10.1007/978-1-4939-9158-7_7.

PMID:
30919350
2.

GPCR Signaling Regulation: The Role of GRKs and Arrestins.

Gurevich VV, Gurevich EV.

Front Pharmacol. 2019 Feb 19;10:125. doi: 10.3389/fphar.2019.00125. eCollection 2019. Review.

3.

Arrestin mutations: Some cause diseases, others promise cure.

Gurevich VV, Gurevich EV.

Prog Mol Biol Transl Sci. 2019;161:29-45. doi: 10.1016/bs.pmbts.2018.09.004. Epub 2018 Oct 24.

PMID:
30711028
4.

The structural basis of the arrestin binding to GPCRs.

Gurevich VV, Gurevich EV.

Mol Cell Endocrinol. 2019 Mar 15;484:34-41. doi: 10.1016/j.mce.2019.01.019. Epub 2019 Jan 28. Review.

PMID:
30703488
5.

Arrestin-mediated signaling: Is there a controversy?

Gurevich VV, Gurevich EV.

World J Biol Chem. 2018 Dec 12;9(3):25-35. doi: 10.4331/wjbc.v9.i3.25. Review.

6.

Cleavage of arrestin-3 by caspases attenuates cell death by precluding arrestin-dependent JNK activation.

Kook S, Vishnivetskiy SA, Gurevich VV, Gurevich EV.

Cell Signal. 2019 Feb;54:161-169. doi: 10.1016/j.cellsig.2018.11.023. Epub 2018 Dec 4.

PMID:
30529266
7.

Arrestins: Introducing Signaling Bias Into Multifunctional Proteins.

Gurevich VV, Chen Q, Gurevich EV.

Prog Mol Biol Transl Sci. 2018;160:47-61. doi: 10.1016/bs.pmbts.2018.07.007. Epub 2018 Sep 6.

PMID:
30470292
8.

Arrestins and G proteins in cellular signaling: The coin has two sides.

Gurevich VV, Gurevich EV.

Sci Signal. 2018 Sep 25;11(549). pii: eaav1646. doi: 10.1126/scisignal.aav1646. Review.

9.

Enhanced Mutant Compensates for Defects in Rhodopsin Phosphorylation in the Presence of Endogenous Arrestin-1.

Samaranayake S, Song X, Vishnivetskiy SA, Chen J, Gurevich EV, Gurevich VV.

Front Mol Neurosci. 2018 Jun 18;11:203. doi: 10.3389/fnmol.2018.00203. eCollection 2018.

10.

GPCRs and Signal Transducers: Interaction Stoichiometry.

Gurevich VV, Gurevich EV.

Trends Pharmacol Sci. 2018 Jul;39(7):672-684. doi: 10.1016/j.tips.2018.04.002. Epub 2018 May 5. Review.

11.

Arrestins: structural disorder creates rich functionality.

Gurevich VV, Gurevich EV, Uversky VN.

Protein Cell. 2018 Dec;9(12):986-1003. doi: 10.1007/s13238-017-0501-8. Epub 2018 Feb 16. Review.

12.

Molecular Defects of the Disease-Causing Human Arrestin-1 C147F Mutant.

Vishnivetskiy SA, Sullivan LS, Bowne SJ, Daiger SP, Gurevich EV, Gurevich VV.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):13-20. doi: 10.1167/iovs.17-22180.

13.

Molecular Mechanisms of GPCR Signaling: A Structural Perspective.

Gurevich VV, Gurevich EV.

Int J Mol Sci. 2017 Nov 24;18(12). pii: E2519. doi: 10.3390/ijms18122519. Review.

14.

Non-visual arrestins regulate the focal adhesion formation via small GTPases RhoA and Rac1 independently of GPCRs.

Cleghorn WM, Bulus N, Kook S, Gurevich VV, Zent R, Gurevich EV.

Cell Signal. 2018 Jan;42:259-269. doi: 10.1016/j.cellsig.2017.11.003. Epub 2017 Nov 11.

15.

Structural basis of arrestin-3 activation and signaling.

Chen Q, Perry NA, Vishnivetskiy SA, Berndt S, Gilbert NC, Zhuo Y, Singh PK, Tholen J, Ohi MD, Gurevich EV, Brautigam CA, Klug CS, Gurevich VV, Iverson TM.

Nat Commun. 2017 Nov 10;8(1):1427. doi: 10.1038/s41467-017-01218-8.

16.

Uncovering missing pieces: duplication and deletion history of arrestins in deuterostomes.

Indrischek H, Prohaska SJ, Gurevich VV, Gurevich EV, Stadler PF.

BMC Evol Biol. 2017 Jul 6;17(1):163. doi: 10.1186/s12862-017-1001-4.

17.

Arrestin-2 and arrestin-3 differentially modulate locomotor responses and sensitization to amphetamine.

Zurkovsky L, Sedaghat K, Ahmed MR, Gurevich VV, Gurevich EV.

Neuropharmacology. 2017 Jul 15;121:20-29. doi: 10.1016/j.neuropharm.2017.04.021. Epub 2017 Apr 15.

18.

G protein-coupled receptor kinases as regulators of dopamine receptor functions.

Gurevich EV, Gainetdinov RR, Gurevich VV.

Pharmacol Res. 2016 Sep;111:1-16. doi: 10.1016/j.phrs.2016.05.010. Epub 2016 May 10. Review.

19.

Peptide mini-scaffold facilitates JNK3 activation in cells.

Zhan X, Stoy H, Kaoud TS, Perry NA, Chen Q, Perez A, Els-Heindl S, Slagis JV, Iverson TM, Beck-Sickinger AG, Gurevich EV, Dalby KN, Gurevich VV.

Sci Rep. 2016 Feb 12;6:21025. doi: 10.1038/srep21025.

20.

Unraveling the Mechanism of Dyskinesia One Transcription Factor at a Time.

Gurevich EV.

Biol Psychiatry. 2016 Mar 1;79(5):338-340. doi: 10.1016/j.biopsych.2015.12.005. No abstract available.

PMID:
26847658
21.

Analyzing the roles of multi-functional proteins in cells: The case of arrestins and GRKs.

Gurevich VV, Gurevich EV.

Crit Rev Biochem Mol Biol. 2015;50(5):440-52. doi: 10.3109/10409238.2015.1067185. Review.

22.

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E.

Prog Neurobiol. 2015 Sep;132:96-168. doi: 10.1016/j.pneurobio.2015.07.002. Epub 2015 Jul 21. Review.

PMID:
26209473
23.

Arrestins: Critical Players in Trafficking of Many GPCRs.

Gurevich VV, Gurevich EV.

Prog Mol Biol Transl Sci. 2015;132:1-14. doi: 10.1016/bs.pmbts.2015.02.010. Epub 2015 Mar 25. Review.

24.

GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain.

Ahmed MR, Bychkov E, Li L, Gurevich VV, Gurevich EV.

Sci Rep. 2015 Jun 4;5:10920. doi: 10.1038/srep10920.

25.

G Protein-coupled Receptor Kinases of the GRK4 Protein Subfamily Phosphorylate Inactive G Protein-coupled Receptors (GPCRs).

Li L, Homan KT, Vishnivetskiy SA, Manglik A, Tesmer JJ, Gurevich VV, Gurevich EV.

J Biol Chem. 2015 Apr 24;290(17):10775-90. doi: 10.1074/jbc.M115.644773. Epub 2015 Mar 13.

26.

Arrestin-3-Dependent Activation of c-Jun N-Terminal Kinases (JNKs).

Zhan X, Kook S, Kaoud TS, Dalby KN, Gurevich EV, Gurevich VV.

Curr Protoc Pharmacol. 2015 Mar 2;68:2.12.1-2.12.26. doi: 10.1002/0471141755.ph0212s68.

27.

Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.

Ahmed MR, Bychkov E, Kook S, Zurkovsky L, Dalby KN, Gurevich EV.

Exp Neurol. 2015 Apr;266:42-54. doi: 10.1016/j.expneurol.2015.02.008. Epub 2015 Feb 14.

28.

G protein-coupled receptor kinases: from molecules to diseases.

Gurevich EV, Premont RT, Gainetdinov RR.

FASEB J. 2015 Feb;29(2):361-4. doi: 10.1096/fj.14-263657ufm. No abstract available.

29.

Beyond traditional pharmacology: new tools and approaches.

Gurevich EV, Gurevich VV.

Br J Pharmacol. 2015 Jul;172(13):3229-41. doi: 10.1111/bph.13066. Epub 2015 Jun 10. Review.

30.

Arrestins regulate cell spreading and motility via focal adhesion dynamics.

Cleghorn WM, Branch KM, Kook S, Arnette C, Bulus N, Zent R, Kaverina I, Gurevich EV, Weaver AM, Gurevich VV.

Mol Biol Cell. 2015 Feb 15;26(4):622-35. doi: 10.1091/mbc.E14-02-0740. Epub 2014 Dec 24.

31.

Overview of different mechanisms of arrestin-mediated signaling.

Gurevich VV, Gurevich EV.

Curr Protoc Pharmacol. 2014 Dec 1;67:Unit 2.10.1-9. doi: 10.1002/0471141755.ph0210s67. Review.

32.

Extensive shape shifting underlies functional versatility of arrestins.

Gurevich VV, Gurevich EV.

Curr Opin Cell Biol. 2014 Apr;27:1-9. doi: 10.1016/j.ceb.2013.10.007. Epub 2013 Nov 16. Review.

33.

Arrestin makes T cells stop and become active.

Gurevich VV, Gurevich EV.

EMBO J. 2014 Mar 18;33(6):531-3. doi: 10.1002/embj.201387724. Epub 2014 Feb 6.

34.

Arrestins in apoptosis.

Kook S, Gurevich VV, Gurevich EV.

Handb Exp Pharmacol. 2014;219:309-39. doi: 10.1007/978-3-642-41199-1_16.

35.

Arrestin-dependent activation of JNK family kinases.

Zhan X, Kook S, Gurevich EV, Gurevich VV.

Handb Exp Pharmacol. 2014;219:259-80. doi: 10.1007/978-3-642-41199-1_13.

36.

Enhanced phosphorylation-independent arrestins and gene therapy.

Gurevich VV, Song X, Vishnivetskiy SA, Gurevich EV.

Handb Exp Pharmacol. 2014;219:133-52. doi: 10.1007/978-3-642-41199-1_7.

37.

Therapeutic potential of small molecules and engineered proteins.

Gurevich EV, Gurevich VV.

Handb Exp Pharmacol. 2014;219:1-12. doi: 10.1007/978-3-642-41199-1_1.

38.

Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding.

Kook S, Zhan X, Kaoud TS, Dalby KN, Gurevich VV, Gurevich EV.

J Biol Chem. 2013 Dec 27;288(52):37332-42. doi: 10.1074/jbc.M113.510412. Epub 2013 Nov 20.

39.

Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release and cell death.

Kook S, Zhan X, Cleghorn WM, Benovic JL, Gurevich VV, Gurevich EV.

Cell Death Differ. 2014 Jan;21(1):172-84. doi: 10.1038/cdd.2013.143. Epub 2013 Oct 18.

40.

Rapid degeneration of rod photoreceptors expressing self-association-deficient arrestin-1 mutant.

Song X, Seo J, Baameur F, Vishnivetskiy SA, Chen Q, Kook S, Kim M, Brooks EK, Altenbach C, Hong Y, Hanson SM, Palazzo MC, Chen J, Hubbell WL, Gurevich EV, Gurevich VV.

Cell Signal. 2013 Dec;25(12):2613-24. doi: 10.1016/j.cellsig.2013.08.022. Epub 2013 Sep 3.

41.

Structural determinants of arrestin functions.

Gurevich VV, Gurevich EV.

Prog Mol Biol Transl Sci. 2013;118:57-92. doi: 10.1016/B978-0-12-394440-5.00003-6. Review.

42.

Distinct cellular and subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in the striatum.

Bychkov E, Zurkovsky L, Garret MB, Ahmed MR, Gurevich EV.

PLoS One. 2012;7(11):e48912. doi: 10.1371/journal.pone.0048912. Epub 2012 Nov 6.

43.

Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.

Zurkovsky L, Bychkov E, Tsakem EL, Siedlecki C, Blakely RD, Gurevich EV.

Dis Model Mech. 2013 Jan;6(1):171-83. doi: 10.1242/dmm.010363. Epub 2012 Aug 3.

44.

Synthetic biology with surgical precision: targeted reengineering of signaling proteins.

Gurevich VV, Gurevich EV.

Cell Signal. 2012 Oct;24(10):1899-908. doi: 10.1016/j.cellsig.2012.05.012. Epub 2012 Jun 1. Review.

45.

Silent scaffolds: inhibition OF c-Jun N-terminal kinase 3 activity in cell by dominant-negative arrestin-3 mutant.

Breitman M, Kook S, Gimenez LE, Lizama BN, Palazzo MC, Gurevich EV, Gurevich VV.

J Biol Chem. 2012 Jun 1;287(23):19653-64. doi: 10.1074/jbc.M112.358192. Epub 2012 Apr 20.

46.

The origin and evolution of G protein-coupled receptor kinases.

Mushegian A, Gurevich VV, Gurevich EV.

PLoS One. 2012;7(3):e33806. doi: 10.1371/journal.pone.0033806. Epub 2012 Mar 19.

47.

Role of receptor-attached phosphates in binding of visual and non-visual arrestins to G protein-coupled receptors.

Gimenez LE, Kook S, Vishnivetskiy SA, Ahmed MR, Gurevich EV, Gurevich VV.

J Biol Chem. 2012 Mar 16;287(12):9028-40. doi: 10.1074/jbc.M111.311803. Epub 2012 Jan 24.

48.

G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.

Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV.

Pharmacol Ther. 2012 Jan;133(1):40-69. doi: 10.1016/j.pharmthera.2011.08.001. Epub 2011 Aug 26. Review.

49.

The functional cycle of visual arrestins in photoreceptor cells.

Gurevich VV, Hanson SM, Song X, Vishnivetskiy SA, Gurevich EV.

Prog Retin Eye Res. 2011 Nov;30(6):405-30. doi: 10.1016/j.preteyeres.2011.07.002. Epub 2011 Jul 29. Review.

50.

Progressive reduction of its expression in rods reveals two pools of arrestin-1 in the outer segment with different roles in photoresponse recovery.

Cleghorn WM, Tsakem EL, Song X, Vishnivetskiy SA, Seo J, Chen J, Gurevich EV, Gurevich VV.

PLoS One. 2011;6(7):e22797. doi: 10.1371/journal.pone.0022797. Epub 2011 Jul 26.

Supplemental Content

Loading ...
Support Center